|Publication number||US7632306 B2|
|Application number||US 10/612,082|
|Publication date||Dec 15, 2009|
|Filing date||Jul 2, 2003|
|Priority date||Jul 20, 1999|
|Also published as||DE69931401D1, DE69931401T2, EP1202683A1, EP1202683B1, US6616699, US6702848, US20010002444, US20040006383, WO2001005333A1|
|Publication number||10612082, 612082, US 7632306 B2, US 7632306B2, US-B2-7632306, US7632306 B2, US7632306B2|
|Inventors||Peter Paul Zilla, Deon Bezuidenhout|
|Original Assignee||Medtronic, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (44), Non-Patent Citations (19), Referenced by (3), Classifications (12), Legal Events (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is a Continuation of application Ser. No. 09/434,649 filed Nov. 5, 1999 now U.S. Pat. No. 6,702,848.
This application claims the benefit of U.S. Provisional Applications Ser. No. 60/144,704 filed Jul. 20, 1999 and Utility Application Ser. No. 09/434,649 filed Nov. 5, 1999.
This invention is directed to a vascular prosthesis having a well-defined pore structure to allow uninterrupted ingrowth of connective tissue into the wall of the prosthesis. Furthermore, mechanical properties of the prosthesis are matched with mechanical properties of a host vessel, thereby overcoming problems of compliance mismatch.
Since the early 1950's, when Voorhees observed an essentially thrombus-free silk thread in a prosthesis explanted from a dog, various polymeric materials have been evaluated for use in porous vascular prostheses. Most commercially available synthetic vascular grafts presently in use are made from either expanded polytetrafluoroethylene (e-PTFE), or woven, knitted, or velour design polyethylene terephthalate (PET or Dacron). Dacron grafts are normally used for large vessel replacement (12-22 mm), whereas e-PTFE is generally used for intermediate diameters (6-12 mm). These conventional prosthetic vascular grafts do not permit unrestricted vessel ingrowth from surrounding tissue due mostly to ingrowth spaces that are either too narrow or discontinuous. When used for smaller diameters, these grafts often fail early due to occlusion by thrombosis (fibrous tissue build up) or kinking, or at a later stage because of anastomotic or neointimal hyperplasia (exuberant muscle growth at the interface between artery and graft). Compliance mismatch between the host artery and the synthetic vascular prosthesis, which may result in anastomotic rupture, disturbed flow patterns and increased stresses, is thought to be a causative factor in graft failure. Other causative factors may include the thrombogenicity of the grafts or the hydraulic roughness of the surface, especially in crimped grafts.
In attempts to facilitate ingrowth, the pore size of commercial e-PTFE grafts has been increased. Due to the irregular structure of the pores (between the nodes and internodular fibers), the available ingrowth spaces rapidly narrow down to sub-arteriole dimensions. Various researchers have produced “foam type” grafts, and although compliance matching was achieved to some extent by some, the structures obtained by them have certain disadvantages that prohibit or inhibit the ingrowth of connective tissue. These disadvantages include closed external and/or internal surfaces, closed or semi-closed cell structures with little or no inter-pore communication, and irregularly shaped and sized pores due to irregular filler materials used in the processes.
Because of their unique combination of physical, chemical and biocompatible properties, polyurethanes have been studied and used in medical devices for over thirty years. Enzymatic hydrolysis, auto-oxidation, mineralization, and biologically induced environmental stress cracking of polyester- and polyetherurethanes have led manufacturers of medical polyurethanes to develop more specialized formulations to prevent these occurrences. These new generation polyurethane elastomers are being increasingly accepted as the biomaterials of choice in most applications, especially those requiring compliance. It is not surprising, therefor, that many researchers have used various polyurethane compositions (and other elastomers) to produce vascular grafts. Salt casting, phase inversion, spraying, and replamineform techniques have been used to produce sponge-like structures containing ill-defined pores, while filament winding and electrostatic spinning result in the formation of filamentous or fibrous structures. In the production of many of these devices, researchers have been able to approximate the compliance of natural blood vessels by careful manipulation of the process variables. Nevertheless, the performance of these experimental grafts is generally unsatisfactory. This indicates that compliance matching alone does not result in the desired healing patterns.
There is thus a need or desire in the vascular prosthesis industry for a vascular graft having a well-defined pore structure in its walls to allow uninterrupted ingrowth of connective tissue into the walls of the prosthesis, wherein the problems of compliance mismatch are overcome.
The present invention is directed to a graft with a porous wall structure containing interconnecting, uniformly shaped pores (i.e. voids) having average diameters between 10 and 300 μm, more preferably 40-110 μm. The standard deviation of the diameters of the pores is typically less than 20 μm, more preferably less than 10 μm. The openings between the pores are typically in the order of 1-100 μm, more typically 20-50 μm, depending on the size of the pores. The pores (i.e. voids) in the structure have well-defined, preferably spherical shapes, and the sizes of the ingrowth spaces are readily optimized for uninterrupted tissue and vessel ingrowth. The problem of compliance mismatch encountered with conventional grafts is also addressed by matching mechanical properties of the graft with mechanical properties of a host vessel. These mechanical properties include smoothness, elasticity and structural integrity.
Several different methods can be used to produce the graft of the present invention. In one method, a tube is fashioned from an elastomeric polymer, for example, by molding an admixture of polymer, solvent (for the polymer), and spherical, soluble microbeads of a desired diameter. Extraction of the beads and precipitation of the polymer renders a tubular structure containing well-defined pores (in the tube wall) suitable for use as a synthetic, small-diameter vascular graft prosthesis.
In other methods, a paste comprising a polymer solution, for example, and an extractable filler is prepared and either rolled onto a mandrel, deposited as layers onto a mandrel, or extruded through an annular orifice. The polymer is then precipitated and the filler is extracted.
An alternative method for making the invention involves melt extrusion of a thermoplastic elastomer with blowing agents to create porosity.
With the foregoing in mind, it is a feature and advantage of the invention to provide a synthetic vascular graft that contains interconnecting, well-defined pores.
It is also a feature and advantage of the invention to provide a graft with a porous wall structure containing pores in a very narrow size range.
It is another feature and advantage of the invention to provide a graft with well-defined pores wherein the sizes of the ingrowth spaces are readily optimized for uninterrupted tissue and vessel ingrowth into the wall of the prosthesis.
It is yet another feature and advantage of the invention to provide a graft wherein mechanical properties of the graft are matched with mechanical properties of the host vessel, thereby overcoming problems of compliance mismatch.
It is a further feature and advantage of the invention to provide a method for producing a graft with interconnecting, well-defined pores.
The term “extractable filler” means any polymeric or other filler material that is soluble and/or extractable by a solvent other than the solvent used for the graft material. The material is preferably spherical in shape with average diameters ranging in size from 10 to 300 micrometers, more preferably from 40 to 110 micrometers. The beads are fractionated according to size, for example by sieving so that the individual fractions have a narrow size distribution. One example would be beads with a diameter of 85±10 μm, where 85 indicates the average size and 10 μm indicates the standard deviation. Examples of suitable materials include protein beads, e.g. alginate, gelatin, carbohydrates (sugar, dextrose, etc.), inorganic and organic salts. Water soluble fillers are suitable when water is the precipitation solvent and the filler extractor.
The term “filler extraction solvent” means any solvent capable of dissolving the extractable filler without adversely affecting the graft structure. For example, water is a suitable filler extraction solvent for water soluble fillers.
The term “precipitation solvent” means any solvent that is capable of precipitating the graft material from solution. The precipitation solvent and the graft material solvent are usually miscible in all proportions. Examples of suitable precipitation solvents include: water, ethanol, acetone, or combinations of any of these. The filler extraction solvent and the precipitation solvent may or may not be the same solvent.
The term “graft material” means any polymeric or other material that can be dissolved in a suitable solvent and re-solidified after graft manufacture by air-drying, phase inversion, or combinations thereof. Examples of suitable graft materials include: thermoplastic elastomers including thermoplastic polyurethanes, e.g. Pellethane, Biomer type polyurethanes, Chronoflex, Hydrothane, Estane, Elast-Eon, Texin, Biomer, Surethane, Corethane, Carbothane, Techoflex, Tecothane and Biospan. In particular, a polyurethane developed by Medtronic and described in U.S. Pat. No. 4,873,308 is an example of a suitable graft material.
The term “graft material solvent” means any solvent capable of dissolving the graft material. Examples of suitable solvents for polyurethanes include: N-methyl pyrrolidone (NMP), N,N dimethyl diacetamide (DMAC), 1,4 dioxane, etc.
The term “graft material solution” means a solution of the graft material in the graft material solvent in concentrations ranging from 1 to 40% by mass, more typically 5 to 30% by mass, usually 10 to 25% by mass.
The term “graft material paste” means an admixture consisting of a graft material solution and an extractable filler. The ratio of filler to graft material in the solution can range from 20:1 to 1:1, more typically from 10:1 to 5:1 (ratios by mass).
The term “chemical blowing agent” means any material that decomposes to form a gas, e.g. CO2 or N2, wherein the gas creates pores in the graft material. Examples of chemical blowing agents include bicarbonates, N-nitroso compounds, azides, azodicarbonamides, and a variety of other agents.
The term “physical blowing agent” means either a liquid or a gas that is introduced to molten graft material under pressure, wherein evaporation of the liquid or expansion of the gas creates bubbles that form pores in the graft material. Examples of physical blowing agents include: chloro-fluoro carbons (e.g. freon), pentane, and hexane.
An improved prosthetic vascular graft can be created with a synthetic scaffold of transmural ingrowth channels which are characterized by a continuous, uninterrupted, well-defined dimension. A simulated cell structure with unit cells approximating pentagonal dodecahedrons allows such channels to be formed. A unit cell created in a foam type structure can be, and often is, represented by an idealized pentagonal dodecahedron. A process for producing such well-defined pores (i.e. voids) in a synthetic scaffold can be achieved using spherical, soluble microbeads as an extractable filler. The process is explained in detail below.
In addition to providing well-defined pores, in order to promote ingrowth of connective tissue, it is important that mechanical properties of the graft (especially smoothness, elasticity and structural integrity) are matched with mechanical properties of the host vessel, thereby overcoming problems of compliance mismatch. Although the structure of blood vessels varies through the body, a “typical” artery includes three distinct layers, each performing specific basic functions. An intima, which includes an endothelium attached to a basement membrane, provides a non-thrombogenic blood contacting surface. A media contains smooth muscle cells (SMC's) as well as elastic and other intercellular connective and matrix materials, and supplies two other important properties to the blood vessel, namely compliance and contractility. In order to achieve these properties, the tissues are oriented in a helical fashion in this medial layer. Another important property, namely structural integrity, is provided by an adventitia. The configuration of collagen fibers in this layer provides for “stiffening” of the vessel when subjected to high internal pressures, i.e. a decrease in compliance with increased strain.
In designing the vascular prosthesis of the invention to result in formation of a neo-artery mimicking the properties of a natural vessel, material for the scaffold should have biostability, processability, availability, and desirable mechanical properties. The porous scaffold should provide high porosity for maximal cell ingrowth and minimal bulk compressibility (to allow for compressibility associated with contractility). The prosthesis should have structural integrity and viscoelastic properties similar to those observed for natural vessels. Furthermore, in order to minimize foreign body reaction and to encourage differential cell ingrowth, the scaffold should also exhibit long-term in-vivo stability. Examples of suitable scaffold materials include thermoplastic elastomers, particularly thermoplastic polyurethanes. The well-defined porosity should be oriented in such a way as to allow for circumferential and longitudinal orientation from radial ingrowth to allow physiological contractility. Such orientation is provided by the pentagonal dodecahedron, as illustrated in
Selection of a suitable filler material to create the pores requires careful consideration. When choosing an extractable filler material, the material should be: non-soluble in the solvent used to dissolve the scaffold material; readily soluble in the precipitation solution or other non-solvent for the scaffold material; crush resistant to withstand mixing and forming of pastes; and non-toxic.
Fractionated salt crystals (NaHCO3, and others) are a ready source of extractable fillers. However, their aspect ratios and fairly wide size distributions (even after careful sieving) make them less than ideal candidates for use in the production of foamed structures. Spherical, soluble microbeads can be manufactured to narrow tolerances. The use of these spherical beads contributes to the production of porous “foam” scaffolds that are much better defined than those obtainable from salt crystals.
The extractable filler comprises uniformly shaped particles, preferably spherical in shape. The average diameters of the particles, as well as the resulting pores, range in size from 10 to 300 micrometers, more preferably from 40 to 110 micrometers. The standard deviation of the particle diameters and corresponding pore sizes are preferably within a controlled range of 20 μm of one another, more preferably within 10 μm of one another. In an embodiment wherein the particles and pores are not spherical but are uniformly shaped, the particles and pores can still be maintained in a controlled range of volume. For example, spherical particles and pores having diameters maintained in a controlled range where the standard deviation is less than 20 μm will correspondingly have volumes maintained in a controlled range where the standard deviation will be less than 4.2×10−6 mm3 (volume of a sphere=4/3π(radius)3). Similarly, non-spherical particles and pores that are uniformly shaped can have volumes maintained in a controlled range where the standard deviation will be less than 4.2×10−6 mm3.
Several different methods can be used to produce the vascular grafts of the present invention. The most preferred method for producing the grafts of the present invention is a vacuum impregnation technique. Referring to
The molds 24 are cylindrical tubes made of glass or other suitable materials with an inside diameter corresponding to a desired outside diameter of a resulting graft. The molds 24 are used in conjunction with cylindrical central rods 18. The cylindrical central rods 18 are made of stainless steel, glass or other suitable materials with an outside diameter corresponding to a desired inner diameter of a resulting graft. Also used in conjunction with the molds 24 is a reservoir 30 for graft material solution and a centralizing spacer 32.
Once the casting device 16 is assembled, the grafts are formed by filling an annular space 34 between the central rod 18 and the tube 24 with an extractable filler. Suitable filler materials include alginate, gelatin, carbohydrates, inorganic and organic salts. The reservoir 30 is filled with a graft material solution comprising graft material in a graft material solvent. Suitable graft materials include thermoplastic elastomers including thermoplastic polyurethanes, such as Pellethane, Biomer type polyurethanes, Chronoflex and Hydrothane. In particular, a polyurethane developed by Medtronic and described in U.S. Pat. No. 4,873,308 is an example of a suitable graft material. Suitable graft material solvents include N-methyl pyrrolidone (NMP), N,N dimethyl diacetamide (DMAC), 1,4 dioxane, etc. Concentration of the graft material in the graft material solvent ranges from 1 to 40% by mass, more typically 5 to 30% by mass, usually 10 to 25% by mass. The concentration depends on various factors, including composition of the graft material, composition of the graft material solvent, and viscosity of the solution. The top manifold 20 is then closed and pressure 22 is applied to the top manifold 20 and/or vacuum 28 is applied to the bottom manifold 26 to force the graft material solution into interstices between the packed extractable filler. The amount of pressure should be on the order of about atmospheric to 15 bar, more preferably 5 to 8 bar. The amount of vacuum should be on the order of about atmospheric to −1 bar, more typically about −0.9 bar.
After the graft material solution is forced into the interstices, the tube 24, graft and rod 18 are removed from the device 16. Precipitation of the graft (defined as removal of the graft material solvent) is begun with immersion into precipitation solvent. Suitable precipitation solvents include water, ethanol, acetone, or combinations of any of these. The central rod 18 is then removed from the graft and the tube 24. Precipitation of the graft material and extraction of the graft material solvent are completed by extended immersion in the precipitation solvent. The precipitated graft is removed from the tube 24. The extractable filler is extracted from the precipitated graft material to produce the porous structure of the invention. The filler can be extracted using a filler extraction solvent, such as water. The precipitation and extraction may be effected either simultaneously or consecutively.
Another method for producing the porous structure of the invention is a paste molding technique. In this method, a paste is prepared from an extractable filler and a graft material solution including graft material and graft material solvent, as described above. The paste contains the filler and the graft material in a ratio of mass between 20:1 and 1:1, respectively. More typically the ratio is between 10:1 and 5:1. A desired thickness of paste is rolled onto a mandrel, wherein the mandrel has an outer diameter equal to a desired internal diameter of a resulting graft. The internal diameter of the graft is preferably between 1 mm and 20 mm, more preferably in the range of 2 to 6 mm for small diameter vessel replacement. The thickness of the paste can vary from 0.1 to 5 mm, more preferably from 0.4 to 1.5 mm, depending on the diameter of the graft. The graft material solution is then precipitated by immersion in precipitation solvent, and the filler is extracted by immersion in a filler extraction solvent, as described above. The precipitation and extraction may be effected either simultaneously or consecutively.
Yet another method for producing the porous structure of the invention is a paste extrusion technique. In this method, a paste is prepared from an extractable filler and a graft material solution comprising graft material and graft material solvent, as described above. The paste is extruded through an annular orifice. The graft material solution is then precipitated by immersion in precipitation solvent, and the filler is extracted by immersion in filler extraction solvent. The precipitation and extraction may be effected either simultaneously or consecutively.
A further method for producing the porous structure of the invention is a dip coating technique. In this method, a paste is prepared (as described above) from an extractable filler and a graft material solution including graft material and graft material solvent. The paste is deposited in consecutive layers onto a mandrel. The graft material solution is then precipitated by immersion in precipitation solvent, and the filler is extracted by immersion in filler extraction solvent. The precipitation and extraction may be effected either simultaneously or consecutively.
Another method for producing the porous structure of the invention is a melt extrusion technique. In this method, a thermoplastic elastomer is extruded with the use of physical and/or chemical blowing agents to produce a foamed graft. Suitable thermoplastic elastomers include thermoplastic polyurethanes, such as Pellethane, Biomer type polyurethanes, Chronoflex, and Hydrothane. Suitable chemical blowing agents include sodium bicarbonate and azodicarbonamides. Suitable physical blowing agents include chloro-fluoro carbons (e.g. freon), pentane, and hexane. The foamed graft is then annealed and reticulated, where needed, to effect an open-cell structure.
There are various types of post-treatment for converting closed cell foams to open cell foams, which essentially entails removing a thin membrane between the cells or pores. One method involves heat treatment. By treating the closed cell foam in a controlled, elevated temperature environment, it is possible to melt the thin membrane without melting the rest of the material. The temperature depends on the graft material. Another method for converting closed cell foams to open cell foams is a mechanical method. By crushing the closed cell foam between rollers or a similar device, the thin membrane will rupture due to the pressure in the pore. A third method is another mechanical method wherein explosive gasses (e.g. stoichiometric ratios of O2/H2) are infiltrated into the pores. The cells are ruptured by ignition of these gasses. Yet another method is a chemical method whereby the foam is subjected to hydrolysis, thereby destroying the thinner membranes more rapidly than the thicker ribs defining the pores. Any of these methods can be used alone or in combination to produce open cell foams.
A final method of producing the graft involved the use of a process whereby the foamed tube is formed by the reaction of monomeric substances (e.g. diisocyanates and diols when polyurethanes are required) with suitable blowing agents (e.g. water). As those skilled in the art will know, the reaction of these reagents with one another in an enclosed cylindrical space (reaction injection molding or RIM process) or in a modified extruder assembly would yield the desired porous graft. Reticulation, removal of possible interior and/or exterior skin, and other post production techniques may be employed to produce the open-cell porosities needed for the ingrowth of living tissue.
Static burst tests show that the grafts should easily be able to withstand pressures associated with iliac implantation. However, high porosity scaffolds often lack structural integrity to withstand physiological pressures and stresses caused by sutures at the anastomoses. Reinforcing fibers can be incorporated into the graft design in any of the described methods to alleviate this problem. The reinforcing fibers can be incorporated into the grafts by winding the fibers around the scaffold while the graft material is in a paste or solution form, for example. Suitable fibers include either elastic or non-elastic non-degradable material, or a combination of elastic and non-elastic materials. Additionally, a reinforcing material that is either elastic or non-elastic, and is degradable in vivo, can be used in combination with the non-degradable material to provide initial strength to the graft. The reinforcement material that is degradable in vivo degrades as the graft is populated by ingrowing cells and accompanying extracellular matrix material. Ingrowing material tends to stiffen the graft; therefore, a degradable fiber can be used to give initial strength to the graft without making the graft overly stiff after ingrowth. The non-extractable fiber typically has a diameter ranging in size from 10 to 100 micrometers. Examples of suitable non-elastic, non-degradable materials include polyethylene terephthalate (PET, Dacron) and polytetrafluoroethylene (PTFE). Examples of suitable elastic non-degradable materials include thermoplastic polyurethanes, e.g. M48, Pellethane (or clones), Biomer (or clones), or any other biocompatible elastomer. Degradable polyurethanes can serve as degradable reinforcing fibers.
The above-described methods can, also be used to produce other items, such as, for example, a biosynthetic heart valve, a sewing ring, or a stent.
While the embodiments of the invention described herein are presently preferred, various modifications and improvements can be made without departing from the spirit and scope of the invention. The scope of the invention is indicated by the appended claims, and all changes that fall within the meaning and range of equivalents are intended to be embraced therein.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4286341||May 23, 1979||Sep 1, 1981||Iowa State University Research Foundation, Inc.||Vascular prosthesis and method of making the same|
|US4441215||Feb 23, 1983||Apr 10, 1984||Kaster Robert L||Vascular graft|
|US4459252||Feb 23, 1982||Jul 10, 1984||Macgregor David C||Method of forming a small bore flexible vascular graft involving eluting solvent-elutable particles from a polymeric tubular article|
|US4552707||May 9, 1983||Nov 12, 1985||Ethicon Inc.||Synthetic vascular grafts, and methods of manufacturing such grafts|
|US4605406||Aug 3, 1984||Aug 12, 1986||Medtronic, Inc.||Method for fabricating prosthesis material|
|US4657544||Apr 18, 1984||Apr 14, 1987||Cordis Corporation||Cardiovascular graft and method of forming same|
|US4725273||Aug 20, 1986||Feb 16, 1988||Kanegafuchi Kagaku Kogyo Kabushiki Kaisha||Artificial vessel having excellent patency|
|US4743252||Jan 13, 1986||May 10, 1988||Corvita Corporation||Composite grafts|
|US4784659||Mar 3, 1987||Nov 15, 1988||Intermedicat Gmbh||Vessel and prosthesis impregnated with diisocyanate crosslinked gelatin|
|US4834746||Mar 17, 1986||May 30, 1989||Kanegafuchi Kagaku Kogyo Kabushiki Kaisha||Artificial vessel and process for preparing the same|
|US4842575||Aug 5, 1988||Jun 27, 1989||Meadox Medicals, Inc.||Method for forming impregnated synthetic vascular grafts|
|US4873308||Sep 30, 1988||Oct 10, 1989||Medtronic, Inc.||Biostable, segmented aliphatic polyurethanes and process therefor|
|US4921495||Mar 24, 1986||May 1, 1990||Kanegafachi Kagaku Kogyo Kabushiki Kaisha||Porous artificial vessel|
|US4932964||Dec 1, 1988||Jun 12, 1990||Sulzer Brothers Limited||Artificial body for a prosthesis|
|US4941870||Dec 30, 1988||Jul 17, 1990||Ube-Nitto Kasei Co., Ltd.||Method for manufacturing a synthetic vascular prosthesis|
|US5024671||Sep 19, 1988||Jun 18, 1991||Baxter International Inc.||Microporous vascular graft|
|US5037377||Aug 21, 1986||Aug 6, 1991||Medtronic, Inc.||Means for improving biocompatibility of implants, particularly of vascular grafts|
|US5108424||Jan 28, 1991||Apr 28, 1992||Meadox Medicals, Inc.||Collagen-impregnated dacron graft|
|US5132066||Sep 26, 1990||Jul 21, 1992||Newtec V.P. Limited||Method of forming a bio-compatible vascular prosthesis|
|US5197977||Apr 30, 1992||Mar 30, 1993||Meadox Medicals, Inc.||Drug delivery collagen-impregnated synthetic vascular graft|
|US5314925 *||Dec 3, 1992||May 24, 1994||General Electric Company||Use of polytetrafluoroethylene resins as a nucleating agent for foam molded thermoplastics|
|US5415619||Nov 5, 1993||May 16, 1995||Korea Research Institute Of Chemical Tech.||Method of manufacturing a vascular graft impregnated with polysaccharide derivatives|
|US5474824 *||Jun 29, 1994||Dec 12, 1995||Atrium Medical Corporation||Process for expanding polytetrafluoroethylene and products produced thereby|
|US5549664||May 2, 1994||Aug 27, 1996||Ube Industries, Ltd.||Artificial blood vessel|
|US5584875||Apr 13, 1994||Dec 17, 1996||C. R. Bard, Inc.||Method for making vascular grafts|
|US5628781||Sep 29, 1992||May 13, 1997||Thomas Jefferson University||Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves|
|US5709934||Nov 22, 1994||Jan 20, 1998||Tissue Engineering, Inc.||Bipolymer foams having extracellular matrix particulates|
|US5770417||Feb 28, 1994||Jun 23, 1998||Massachusetts Institute Of Technology Children's Medical Center Corporation||Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo|
|US5807406||Oct 7, 1994||Sep 15, 1998||Baxter International Inc.||Porous microfabricated polymer membrane structures|
|US5891558 *||Nov 21, 1996||Apr 6, 1999||Tissue Engineering, Inc.||Biopolymer foams for use in tissue repair and reconstruction|
|US6056993||Apr 17, 1998||May 2, 2000||Schneider (Usa) Inc.||Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel|
|US6177522 *||Nov 9, 1998||Jan 23, 2001||Salviac Limited||Biostable polycarbonate urethane products|
|US6554857 *||Nov 5, 1999||Apr 29, 2003||Medtronic, Inc||Transmural concentric multilayer ingrowth matrix within well-defined porosity|
|US6702849 *||Dec 13, 1999||Mar 9, 2004||Advanced Cardiovascular Systems, Inc.||Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers|
|EP0286220A1||Feb 29, 1988||Oct 12, 1988||Newtec Vascular Products Ltd.||Methods and apparatus for making polymer material|
|EP0315814A2||Oct 21, 1988||May 17, 1989||Dow Corning Corporation||Methods for forming porous-surfaced polymeric bodies|
|EP0332371A1||Mar 6, 1989||Sep 13, 1989||Dow Corning Wright Corporation||Method for forming hollow, porous-surfaced elastomeric bodies|
|EP0560279A1||Mar 9, 1993||Sep 15, 1993||Ultramet||Open cell tantalum structures for cancellous bone implants and cell and tissue receptors|
|EP0560279B1||Mar 9, 1993||Jun 14, 2000||Ultramet||Open cell tantalum structures for cancellous bone implants and cell and tissue receptors|
|EP0815806A2||Jun 26, 1997||Jan 7, 1998||Cordis Corporation||Controlled porosity endovascular implant|
|WO1990006094A1||Dec 8, 1989||Jun 14, 1990||Brigham And Women's Hospital||Prosthesis of foam and collagen|
|WO1992009652A1||Nov 19, 1991||Jun 11, 1992||Newtec V.P. Limited||Polymer products|
|WO1997015242A1||Oct 25, 1995||May 1, 1997||Seare William J Jr||Porous material product and process|
|WO1997047254A1||Jun 11, 1997||Dec 18, 1997||The Regents Of The University Of Michigan||Compositions and methods for coating medical devices|
|1||Annie et al.,, Trans. Am. Soc. Artif. Intern Organs, vol XXIV, 1978, pp. 209-214.|
|2||Berkowitz, Henry D., et al.,, Amer Soc Artif Int Organs, vol. XVIII, 1972, pp. 25-29.|
|3||Berkowitz, Henry D., M.D., et al., Surgery, vol. 72, No. 6, Dec. 1972, pp. 888-896.|
|4||Edwards, Alan et al., Jrnl of Biomaterials Applications, vol. 10, Oct. 1995, pp. 171-187.|
|5||Hess, F., et al, Biomaterials, vol. 13, No. 10, 1992, pp. 657-663.|
|6||Hess, F., J. Cardiovasc. Surg., 24, 1983, pp. 516-524.|
|7||Hess, F., M.D. et al.,, Jrnl of Cardio Surg, vol. 22, 1992, pp. 358-365.|
|8||Hiratzka, Loren F., M.D., et al., Arch Surg, vol. 114, Jun. 1979, pp. 698-702.|
|9||Ives, C.L., et al.,, Trans Am Soc Artif Intern Organs, vol. XXX, 1984, pp. 587-590.|
|10||Leidner, Jacob et al.,, Jrnl of Biomedical materials Research, vol. 17, pp. 229-247.|
|11||Lyman, D.J., et al.,, Trans Am Soc Artif Intern Organs, vol. XXIII, 1977, pp. 253-261.|
|12||Murabayashi, S. et al.,, Trans Am Sac Artif Intern Organs, vol. XXXI, 1985, pp. 50-55.|
|13||Pollock, E., et al.,, Trans Am Soc Arai Intern Organs, vol. XXVII, 1981, pp. 405-409.|
|14||Uchida, Naold et al.,, Jrnl of Biomedical Materials Research, vol. 27, 1993, pp. 1269-1279.|
|15||Weber, Jon N., et al.,, Science, vol. 176, May 26, 1972, pp. 922-924.|
|16||White, R.A., et al., Science, 1972, 176(37); 922-4.|
|17||White, Rodney, A., et al.,, Surgery, vol. 79, No. 2, Feb 1976, pp. 229-232.|
|18||Williams, Stuart K., et al.,, Jrnl of Biomedical Materials Research, vol. 26, pp. 103-117.|
|19||Wilson, G.J.,, Trans Am Soc Artif Intern Organs, vol. XXIX, 1983, pp. 260-268.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8418297||Dec 30, 2008||Apr 16, 2013||Tempur-Pedic Management, Llc||Reticulated material body support and method|
|US8632489||Dec 22, 2011||Jan 21, 2014||A. Mateen Ahmed||Implantable medical assembly and methods|
|US9381112||Oct 4, 2012||Jul 5, 2016||William Eric Sponsell||Bleb drainage device, ophthalmological product and methods|
|International Classification||A61F2/06, A61L27/56, A61F2/00, A61L27/50|
|Cooperative Classification||A61L27/56, A61L27/507, A61F2/0077, A61F2/06|
|European Classification||A61L27/50E, A61L27/56, A61F2/06|
|Jul 2, 2003||AS||Assignment|
Owner name: MEDTRONIC, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZILLA, PETER PAUL;BEZUIDENHOUT, DEON;REEL/FRAME:014285/0725
Effective date: 19991029
|Nov 2, 2010||CC||Certificate of correction|
|Jul 26, 2013||REMI||Maintenance fee reminder mailed|
|Dec 15, 2013||LAPS||Lapse for failure to pay maintenance fees|
|Feb 4, 2014||FP||Expired due to failure to pay maintenance fee|
Effective date: 20131215